Loading...
As treatment regimens for hepatitis C virus (HCV) infection move beyond interferons and toward direct-acting antiviral agents (DAAs) such as protease inhibitors and RNA polymerase inhibitors, researchers explore a possible future role for targeted, active immunotherapeutics.
In the current open-label, phase II study, investigators assessed the efficacy of TG4040 in patients infected with HCV genotype 1. TG4040 is a derivative of the attenuated nonreplicative vaccinia virus of the strain Ankara (MVA) engineered to express HCV nonstructural proteins NS3, NS4, and NS5B. Patients were randomized in a 1:2:2 ratio into the following groups:
Group A: Thirty-one patients received 180 µg of peginterferon alfa-2a weekly and 1000 to 1200 mg of ribavirin…